Genomic instability of ovarian cancer (OvCa) cells and the resulting frequent loss or reduction of HLA expression and function facilitate immune avoidance of this aggressive cancer. The goal of this Project is to develop an effective mode of immunotherapy capable of targeting both MHC-positive and MHC-negative variants of OvCa and counteracting local immune suppression, known to contribute to poor prognosis in OvCa patients. We observed that type-1-polarized DCs (?DC1s), a novel type of DCs developed by our group, effectively cross-present OvCa-related antigens and induce high numbers of MHC class l-restricted CTLs capable of recognizing defined OvCa-related antigenic epitopes. However aDC1-induced CTLs also express elevated levels of NK receptors, NKG2D- and DNAM1. Such

Public Health Relevance

We plan to develop a new immunotherapy of ovarian cancer, combining a new highly-potent autologous dendritic cells vaccine (?DC1s) with the local infusion of ex-vivo ?DC1-induced effector CD8+ T cells (CTLs) able of recognizing tumor cells both in a classical (TCR-dependent) and TCR-independent manner. We anticipate that such treatment will promote destruction of residual tumor cells in patients with advanced ovarian cancer treated with chemotherapy, independently on their ability to mutate and evade classical forms of immune recognition, preventing or delaying tumor recurrence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA159981-01A1
Application #
8485810
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2013-09-18
Project End
2018-06-30
Budget Start
2013-09-18
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$252,036
Indirect Cost
$41,459
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Szender, J Brian; Eng, Kevin H; Matsuzaki, Junko et al. (2016) HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol 142:158-62
Kohrt, Holbrook E; Tumeh, Paul C; Benson, Don et al. (2016) Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer 4:15
Chen, Yichao; Xia, Rui; Huang, Yixian et al. (2016) An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun 7:13443
Wong, Jeffrey L; Obermajer, Nataša; Odunsi, Kunle et al. (2016) Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res 4:303-11
Shi, Liangrong; Chen, Lujun; Wu, Changping et al. (2016) PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res 22:1173-84
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Winham, Stacey J; Pirie, Ailith; Chen, Yian Ann et al. (2016) Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 25:446-54
Præstegaard, Camilla; Kjaer, Susanne K; Nielsen, Thor S S et al. (2016) The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiol 41:71-9
Earp, Madalene; Winham, Stacey J; Larson, Nicholas et al. (2016) A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget 7:7381-9
Zhao, Wenyuan; Chen, Beibei; Guo, Xin et al. (2016) A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. Oncotarget 7:19060-71

Showing the most recent 10 out of 73 publications